Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploratory Phase II Clinical Trial Comprising Biomarker Analysis of Oxaliplatin Plus Fluorouracil/Leucovorin (FOLFOX) in Combination With Bevacizumab (Bvz) in First Line Treatment of Metastatic Colorectal Cancer (CRC) Expressing Mutant K-ras - AC-ANGIOPREDICT

NCT01822444 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT01822444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01822444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploratory Phase II Clinical Trial Comprising Biomarker Analysis of Oxaliplatin Plus Fluorouracil/Leucovorin (FOLFOX) in Combination With Bevacizumab (Bvz) in First Line Treatment of Metastatic Colorectal Cancer (CRC) Expressing Mutant K-ras - AC-ANGIOPREDICT
Lead sponsor
Cancer Trials Ireland
Phase
Observational
Overall status
Completed
Start date
November 30, 2012
Completion date
February 28, 2017
Enrollment
76 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal cancer